Although the disease is still in the infectious stage, the spread of the Omigran variant could turn Kovit-19 into a native disease that mankind can learn to live in, the European regulator said on Tuesday.
The European Medicines Agency (EMA) has expressed skepticism about providing a fourth vaccine to the population, saying repeated injections are not a “standard” strategy.
“No one knows exactly when we will be at the end of the tunnel, but we will get there,” said Marco Cavaleri, head of the Amsterdam-based EMA’s vaccination strategy.
“With the increase in immunity in the population – and there will be a lot of natural immunity in addition to vaccination with Omicron – we will quickly move towards a situation that is closer to the local disease,” M Cavaleri told a news conference.
But he stressed, “We must not forget that we are still in an epidemic.”
The European Branch of the World Health Organization has stated that it is currently not possible to qualify for a virus such as influenza.
“We still have a virus, it develops very quickly and presents new challenges, so we’re certainly not at the point of qualifying it as local,” said Catherine Smallwood, WHO’s person in charge of emergency situations in Europe.
According to WHO Europe, more than half of Europeans could be affected by the Omicron variant within two months of the current “wave wave” view.
The latter also warned that combating COVID-19 infection with booster doses of current vaccines was not a viable strategy, which was shared by EMA.
“If we had a strategy of providing boosters every four months, we would face immune response issues,” Cavaleri said.
“And secondly, there is a risk that people will get tired of the continuous administration of booster doses,” he added.
Instead, nations should start thinking about giving boosters a break at long intervals and delivering them at the start of winter like a flu shot, he said.
Although Omigran appears to be more contagious than other types, studies show a lower risk of hospitalization after infection with this variant – according to the EMA, the risk of delta variant is estimated to be one-third to one-half. .